ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB, AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB, IN PATIENTS WITH ADVANCED OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA OR MYXOFIBROSARCOMA WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Tracon Pharmaceuticals, Inc.
Start Date
October 23, 2020
End Date
October 31, 2025
Administered By
Duke Cancer Institute
Awarded By
Tracon Pharmaceuticals, Inc.
Start Date
October 23, 2020
End Date
October 31, 2025